The multi-kinase inhibitor Sorafenib increases the survival of patients with advanced hepatocellular carcinoma (HCC). Current data suggest that Sorafenib inhibits cellular proliferation and angiogenesis and promotes apoptosis. However, the underlying pro-apoptotic molecular mechanisms are incompletely understood. Here we compared the pro-apoptotic and anti-proliferative properties of Sorafenib in murine hepatoma cells and syngeneic healthy hepatocytes in vitro and in animal models of HCC and liver regeneration in vivo. In vitro, we demonstrate that cell cycle activity and expression of anti-apoptotic Bcl-2 like proteins are similarly downregulated by Sorafenib in Hepa1-6 hepatoma cells and in syngeneic primary hepatocytes. However, Sorafenibmediated activation of caspase-3 and induction of apoptosis were exclusively found in hepatoma cells, but not in matching primary hepatocytes. We validated these findings in vivo by applying an isograft HCC transplantation model and partial hepatectomy (PH) in C57BL/6 mice. Sorafenib treatment activated caspase-3 and thus apoptosis selectively in small tumor foci that originated from implanted Hepa1-6 cells but not in surrounding healthy hepatocytes. Similarly, Sorafenib did not induce apoptosis after PH. However, Sorafenib treatment transiently inhibited cell cycle progression and resulted in mitotic catastrophe and enhanced non-apoptotic liver injury during regeneration. Importantly, Sorafenib-mediated apoptosis in hepatoma cells was associated with the expression of p53-upregulated-modulator-of-apoptosis (PUMA). In contrast, regenerating livers after PH revealed downregulation of PUMA and were completely protected from Sorafenib-mediated apoptosis. We conclude that Sorafenib induces apoptosis selectively in hepatoma cells but not in healthy hepatocytes and can additionally increase non-apoptotic hepatocyte injury in the regenerating liver.
Subject Category: Cancer
Sorafenib is the only approved drug for the treatment of patients with unresectable hepatocellular carcinoma (HCC) at present. 1, 2 In a phase III double-blind randomized control trial Sorafenib treatment improved overall survival of patients with advanced HCC from 7.9 months in the placebo group to 10.7 months. 3 Deregulated signaling pathways in HCC have been extensively reviewed 4 and include activation of the Raf/ Ras/mitogen-activated protein kinase (MAPK) pathways and over-expression of pro-angiogenic factors such as VEGF and PDGF. Sorafenib is a multi-kinase inhibitor with reported activity against Raf-1, B-Raf, VEGFR2, PDGFR and c-Kit receptors, among other receptor tyrosine kinases and serine threonine kinases 5 and thus acts as an anti-proliferative and an anti-angiogenic agent. The anti-tumor efficacy of Sorafenib in HCC was intensively studied in the two hepatoma cell lines PLC/PRF/5 and HepG2 in vitro and also in vivo using heterotopic xenotransplantation models. 6 These studies revealed that Sorafenib prevents cell cycle progression by inhibiting MAPK and through downregulation of Cyclin D1.
The mitochondrial membrane permeability is predominantly controlled by a balanced expression of pro-apoptotic and anti-apoptotic proteins of the Bcl-2 (B-cell lymphoma) family. Anti-apoptotic Bcl-2 proteins such as Bcl-2, Bcl-Xl and Mcl-1 are responsible for the maintenance of mitochondrial membrane permeability by inhibiting pro-apoptotic proteins and Apaf-1. 7 Sorafenib reduces Mcl-1 expression, which is associated with the induction of apoptosis in some tumor cell lines. 6, 8 However, the pro-apoptotic properties of Sorafenib are incompletely understood.
Here, we aimed to evaluate the potential pro-apoptotic and anti-proliferative effects of Sorafenib on healthy hepatocytes. To this end we compared Sorafenib-dependent signaling pathways in malignant hepatoma cells versus healthy hepatocytes in a syngeneic background in vitro and in vivo. We demonstrate that Sorafenib similarly induces cell cycle arrest in hepatoma cells and in liver after partial hepatectomy (PH) while it specifically induces apoptosis only in malignant hepatoma cells in vitro and in vivo. Interestingly, apoptosis induction was associated with the robust expression of p53-upregulated-modulator-of-apoptosis (PUMA). We also show that Sorafenib may trigger non-apoptotic cell death in regenerating livers by features resembling mitotic catastrophe. Thus, our study provides novel mechanistic data highlighting the benefits and risks of Sorafenib treatment in patients with HCC.
Results
Sorafenib induces cell cycle arrest via suppression of MAPK pathway and G1/S phase cyclins and promotes apoptosis in Hepa1-6 cells. The present study aimed to examine differential effects of Sorafenib on healthy hepatocytes versus malignant transformed hepatoma cells. All experiments were performed in a syngeneic murine system using either the mouse hepatoma cell line Hepa1-6 (derived from C57/LJ mice 9 ) or C56BL/6 mice. First, we determined the dose-dependent effects of Sorafenib on cell cycle progression in Hepa1-6 cells in vitro.
Gene and protein expression analysis revealed that Sorafenib strongly inhibited cell cycle signaling in Hepa1-6 cells. Low Sorafenib concentrations (Z5 mM) resulted in a 50% downregulation of Cyclin E1 gene expression and moderate inhibition of Cyclin D1 and Cyclin A2 transcription (Figure 1a) . On the protein level, Sorafenib concentrations Z10 mM completely abrogated cyclin D1 and substantially reduced the expression of cyclins E1 and A2, respectively (Figure 1b) . This was associated with the lack of Retinoblastoma protein (Rb) phosphorylation and the downregulation of proliferating cell nuclear antigen (PCNA, Figure 1b) . The onset of cell cycle is usually associated with the activation of Ras/Raf signaling involving phosphorylation of MAPK kinases (MEK1/2) and Extracellular-signal-regulated kinases (Erk1/2). Sorafenib dose-dependently inhibited phosphorylation of MEK1/2 and Erk1/2, respectively (Figure 1b) , suggesting that Sorafenib blocks several steps of the Ras/Raf/MAPK pathway in Hepa1-6 cells.
We next studied time-dependent effects of Sorafenib on Hepa1-6 cells using an effective dose of 10 mM. Interestingly, Cyclin E1 gene expression was markedly downregulated already 4 h after Sorafenib treatment, which was not the case for Cyclin A2 and Cyclin D1 (Figure 1c) . Altogether, these data suggest that Sorafenib-dependent inhibition of cell cycle signaling is mediated through several independent transcriptional and post-translational mechanisms in Hepa1-6 cells.
In order to verify that Sorafenib-mediated downregulation of cell cycle signaling results in true cell cycle arrest of Hepa1-6 cells, we measured the incorporation of the nucleoside analog BrdU as a real-time indicator of DNA synthesis (S-phase, Figures 1d and e) . In good agreement with our protein studies, S-phase was slightly reduced by moderate Sorafenib doses (r10 mM), while stronger concentrations resulted in marked inhibition of DNA synthesis. Flow cytometry of propidium iodide (PI)-stained Hepa1-6 cells confirmed these findings and further revealed that increasing amounts of Sorafenib lead to the accumulation of Hepa1-6 cells in a stage with 4n DNA content, indicative of G2/M-phase arrest (Figure 1f ).
In addition, these FACS experiments demonstrated the formation of apoptotic cells with Sorafenib concentrations Z10 mM due to the appearance of a sub-G1 cell population. Of note, the apoptotic cell fraction was B20% of total cells after 50 mM Sorafenib treatment (Figure 1f ). This prompted us to investigate the pro-apoptotic signaling of Sorafenib in more detail. Within 24 h, Sorafenib concentrations Z10 mM resulted in a dose-dependent reduction of cell density, change of morphology and obvious cell death (Figure 2a ). Akt-Kinase activity promotes pro-survival/proliferative and anti-apoptotic pathways on transcriptional and post-translational levels, 10 and was dose-dependently inhibited by Sorafenib (Figure 2b ). In addition, Sorafenib inhibited phosphorylation of the Akt target Mdm2, reduced protein levels of the anti-apoptotic mediators such as Mcl-1, Bcl-2 and Bcl-Xl and promoted strong activation of the pro-apoptotic caspase-3 (Figure 2b ), which resulted in the induction of apoptosis as evidenced by TUNEL-staining (Figure 2c ). Thus, Sorafenib mediates pro-apoptotic and anti-proliferative effects in murine Hepa1-6 hepatoma cells.
Sorafenib abrogates MAPK signaling and cell cycle onset in resting and mitogen-activated primary hepatocytes. We aimed to investigate whether Sorafenib acts similarly on hepatoma cells and healthy hepatocytes of the same genetic origin and thus repeated our previous experiments in primary hepatocytes isolated from C57/BL6 wild-type (WT) mice with increasing concentrations of Sorafenib. Resting, non-stimulated hepatocytes initiate slight DNA replication within 24 h after ex vivo isolation, as indicated by phosphorylation of Rb, Erk1/2 and subsequent onset of PCNA expression (Figure 3a ). Similar to our findings in Hepa1-6 cells, Sorafenib treatment abrogated cell cycle signaling at concentrations Z20 mM (Figure 3a) , suggesting a similar anti-proliferative effect of Sorafenib in hepatocytes and hepatoma cells. Of note, high Sorafenib dosage also inhibited the expression of total Erk1/2 specifically in hepatocytes, but not in Hepa1-6 cells (compare Figure 1b) .
To induce a strong proliferative response that better mimics the continuous proliferation of hepatoma cells, we 11 We thus focused on Sorafenib-mediated effects 48 and 72 h post EGF/insulin treatment as this is apparently Sorafenib signaling in liver and hepatoma cells R Sonntag et al the time frame of maximal DNA replication in mitogenstimulated hepatocytes. On the transcriptional level, the kinetics of Cyclin A2 induction without Sorafenib treatment were in good agreement with our previous data. 11 Low doses of Sorafenib (5 mM) delayed Cyclin A2 induction but still allowed full induction 72 h post treatment ( Figure 3b ). In contrast, Cyclin A2 gene induction was completely blocked by Sorafenib at concentrations Z20 mM (Figure 3b and Supplementary Figure 1A) . Hence, Sorafenib repressed mitogen signaling (pErk1/2) and mediators for S-phase (Cyclin A2, PCNA, pRb) and mitosis (Cyclin B1) posttranscriptionally (Figures 3c and d) . Inhibition of S-phase and cell cycle arrest was confirmed by BrdU incorporation analysis (Figures 3e and f, Supplementary Figure 1B) . EGF/ insulin stimulation alone resulted in sustained DNA synthesis in primary hepatocytes, which was substantially reduced by Sorafenib concentrations Z20 mM. Altogether, Sorafenib similarly inhibits cell cycle initiation in hepatoma cells and non-transformed hepatocytes.
Sorafenib specifically induces caspase-3-mediated apoptosis in malignant transformed hepatocytes in vitro and in vivo. We next tested the pro-apoptotic properties of Sorafenib on ex vivo isolated primary hepatocytes. Following Sorafenib treatment, resting primary hepatocytes showed a dose-dependent reduction of the anti-apoptotic proteins phospho-Mdm2, Bcl-2 and Mcl-1 and inhibition of Akt-Kinase activity similar to hepatoma cells ( Figure 4a, Supplementary Figure 1c) . However, in contrast to Hepa1-6 cells, we did not detect any proteolytic activation of caspase-3 in primary hepatocytes (Figure 4a ), suggesting that the reduction of anti-apoptotic signaling alone is not capable of inducing apoptosis in resting hepatocytes.
We thus tested whether Sorafenib might induce apoptosis in mitogen-activated cells. Therefore, we co-stimulated Sorafenib-treated primary hepatocytes with EGF/insulin and analyzed the apoptotic response 48-72 h after treatment. As observed in hepatoma cells and resting hepatocytes, the anti-apoptotic proteins Bcl-Xl and Bcl-2 were downregulated and phosphorylation of the pro-survival factors pMdm2 and pAkt were inhibited in a dose-dependent manner (Figures 4b and c). However, mitogenic stimulation did not trigger Sorafenib-mediated caspase-3 activation as investigated by immunoblot and caspase-3 enzyme activity assays ( Figures  4c and d) , suggesting that Sorafenib mediates apoptosis specifically in malignant transformed hepatocytes.
To test this hypothesis in vivo we took advantage of the immunocompatibility between C57/BL6 mice and Hepa1-6 cells. We injected 3 Â 10 6 Hepa1-6 cells i.v. into 8-week-old C57/BL6 mice ( Figure 5a ). After 3 weeks small hepatic tumor foci of B50-100 mm diameter were found, which were characterized by high cellular density and strong proliferation as evidenced by nuclear Ki-67 expression (Figures 5b and c) . A cohort of these mice was treated with Sorafenib or solvent for 4 consecutive days and analyzed for intrahepatic caspase-3 activation. Only Sorafenib-treated livers revealed focal caspase-3 activation within engrafted tumor foci, while surrounding resident hepatocytes did not undergo any apoptotic cell death (Figures 5d and e) . These data demonstrated highly specific pro-apoptotic properties of Sorafenib in malignant transformed hepatocytes in vivo.
Sorafenib inhibits hepatic cell cycle progression in vivo after PH. Our previous experiments demonstrated that Sorafenib similarly inhibited cell cycle in healthy and transformed hepatocytes in vitro but did not induce apoptosis of non-malignant hepatocytes. To further evaluate the relevance of this observation in vivo, we performed PH in WT mice that were orally treated with Sorafenib 2 h before and once daily after surgery (Figure 6a ). Animals were killed at the peak of S-phase (48 h post PH) and after terminated regeneration (96 h post PH).
Ki-67 -a general marker for cell cycle activity -is expressed in S, G2 and M-phase. 12 In agreement with earlier studies, B40% of hepatocytes expressed Ki-67 48 h after PH. Interestingly, treatment with ethanol-containing vehicle alone already resulted in a 50% reduction of overall cell cycle activity 48 h after PH. However, Sorafenib treatment further reduced the number of proliferating cells by B60% in comparison to solvent-treated mice. The inhibitory effect of Sorafenib was transient and restricted to 48 h, but not 96 h post PH (Figures  6b and C) . We demonstrated that Sorafenib already inhibited hepatic S-phase at the peak of DNA replication (48 h post PH) as evidenced by BrdU incorporation analysis (Figures 6d  and e) . To further validate these findings, we analyzed expression of cell cycle-specific proteins induced at G1/ S-phase transition (pRb, PCNA), S-phase progression (Cyclin A2) and mitosis (Cyclin B1) in liver samples 48 h after PH. Of note, the solvent alone already had a moderated effect on protein expression, while Sorafenib substantially downregulated all investigated proteins (Figure 6f , Supplementary  Figure 2A) . Strikingly, expression of the cell cycle inhibitor p21 was similar in Sorafenib-and vehicle-treated mice, suggesting that the observed cell cycle arrest in the Sorafenib group was p21-independent (Figure 6f) . Interestingly, vehicle treatment inhibited hepatocyte mitosis as evidenced by histological analysis, which was not further impaired by Sorafenib despite marked Cyclin B1 reduction in this group (Figures 6f and g ).
Continuous Sorafenib uptake induces non-apoptotic liver injury in the regenerating liver through disordered mitosis. We next analyzed the consequences of Sorafenibmediated cell cycle arrest for the regenerating liver after PH. Unexpectedly, 96 h after PH, Sorafenib-treated mice showed normal liver mass reconstitution in comparison to hepatectomized mice with or without vehicle treatment (Figure 7a ), which implies that Sorafenib does not block but rather delays the hepatic cell cycle or alternatively triggers liver mass reconstitution through hypertrophic cell growth of hepatocytes as reported earlier. 13, 14 In agreement with our previous data, we did not detect elevated caspase-3 enzyme activity exceeding background levels in any treatment group after PH (Figure 7b ), further confirming that Sorafenib does not induce apoptosis in nonmalignant hepatocytes independent of their proliferation status. However, Sorafenib-treated mice revealed significantly elevated serum transaminase levels (ALT, AST) 48 and 96 h after PH (Figure 7c ), indicating that Sorafenib triggers enhanced non-apoptotic hepatocyte injury in the regenerating liver, which was not associated with enhanced infiltration of granulocytes (Supplementary Figure 2B-C) .
A thorough histological examination of regenerating livers revealed that Sorafenib treatment triggered aberrant (Figures 7d and e) . Thus, Sorafenib treatment does not induce apoptosis in the regenerating liver but leads to changes in mitosis progression and non-apoptotic liver injury. We finally addressed the important question how Sorafenib induces apoptosis selectively in malignant hepatoma cells. Recent studies indicated that in colon carcinoma cells Sorafenib-mediated apoptosis was associated with the induction of PUMA. 15 We thus measured PUMA gene and protein expression in stimulated hepatoma cells, primary hepatocytes and Sorafenib-treated mice after PH, respectively. On the transcriptional level, PUMA gene expression was substantially higher in hepatoma cells and even further induced after Sorafenib treatment when compared with hepatocytes. Immunoblot analysis revealed robust PUMA protein expression in Hepa1-6 cells with or without Sorafenib treatment but clear decrease of PUMA levels in Sorafenibtreated hepatocytes (Figure 7f ). Following PH, PUMA was significantly downregulated in Sorafenib-treated mice 48 h after PH in both control and Sorafenib-treated groups (Figure 7g ). Altogether, protection from Sorafenibdriven apoptosis was found exclusively in non-malignant hepatocytes with low PUMA levels in vitro and in vivo.
Discussion
The multi-kinase inhibitor Sorafenib is the only approved systemic therapy for patients with advanced HCC so far and results in significant but modest overall survival. 3, 16, 17 Although it is meanwhile well accepted that Sorafenib mediates pleiotropic effects by promoting apoptosis and inhibiting cellular proliferation and angiogenesis, the precise molecular mechanisms are still incompletely understood. For technical and ethical reasons it is obvious that the cellular and molecular effects of Sorafenib cannot be thoroughly analyzed in patients. The majority of previous mechanistic data on the anti-tumor activity of Sorafenib therefore comes from studies in human hepatoma cell lines or from xenograft models in mice and rats. 6, 17, 18 However, these approaches have limitations as they only incompletely reflect the situation in a human liver with advanced HCC, cirrhosis and liver regeneration.
Here, we performed for the first time a comprehensive study of Sorafenib-mediated effects in a homogenous system using mice, primary (healthy) hepatocytes and malignant hepatoma cells with a syngeneic genetic background allowing comparative analyses in vivo and in vitro. We demonstrate that Erksignaling, cell cycle activity and expression of anti-apoptotic Bcl-2 like proteins (Bcl-2, Bcl-XL and Mcl-1) is similarly downregulated by Sorafenib in hepatoma cells derived from C57L mice (Hepa1-6) and in primary hepatocytes from C57BL/6 mice. However, Sorafenib-mediated activation of caspase-3-dependent apoptosis was specifically found in hepatoma cells, but not in healthy hepatocytes. We validated these findings in vivo by applying an isograft HCC transplantation model and after PH in C57BL/6 mice. We provided evidence that Sorafenib activates caspase-3 and thus apoptosis selectively in small tumor foci that originated from implanted Hepa1-6 cells but not in surrounding healthy hepatocytes. Similarly, Sorafenib did not induce apoptosis after PH. However, Sorafenib treatment transiently inhibited cell cycle progression and resulted in incorrect mitosis and enhanced non-apoptotic liver injury during liver regeneration.
Previous studies already demonstrated that Sorafenib efficiently blocks cell cycle initiation in human HCC cell lines by inhibiting Raf/ERK signaling and Cyclin D induction. 6 In our present study we extended these analyses in the murine model and provide new evidence demonstrating that these cell cycle inhibitory effects are a general property of Sorafenib and apply not only for hepatoma cells but also for mitogen-activated healthy hepatocytes in vitro and in vivo. We also addressed the regulatory mechanisms of Sorafenib on downstream G1 and S-phase cyclins, respectively. While Sorafenib downregulated Cyclins D and A predominantly at the protein level, it also showed very strong and fast effects on Cyclin E1 gene transcription. We recently demonstrated that Cyclin E1 is essential for the activation and survival of hepatic stellate cells and induction of liver fibrosis, 19 while its role for liver regeneration in hepatocytes can be replaced by overlapping Cyclins such as Cyclin A2. 20 Thus, application of Sorafenib in patients with chronic liver disease could also act as an anti-fibrotic as suggested earlier. 21 We further conclude that Sorafenib similarly mediates cell cycle arrest in malignant and non-malignant cells such as regenerating healthy hepatocytes via identical mechanisms. This has to be taken into account when applying Sorafenib to patients with advanced cirrhosis as residual liver function in these patients relies on regenerating hepatocytes.
Our finding that Sorafenib specifically activates caspase-3 and apoptosis in malignant hepatoma cells but not in non-malignant hepatocytes under any tested condition in vitro or in vivo is a key result of our study and defines a strong tumor-specific effect of Sorafenib. Our data are in good agreement with a previous paper demonstrating that Sorafenib even protects primary murine hepatocytes from TGF-b-induced apoptosis in vitro. 22 However, the mechanism preventing Sorafenib-mediated apoptosis in healthy hepatocytes remains obscure and needs further investigation. The observed downregulation of the antiapoptotic Bcl-2-like proteins Mcl-1 and Bcl-XL after Sorafenib treatment is not sufficient to explain caspase-3 activation and apoptosis in hepatoma cells in vitro for two reasons. First, Mcl-1 and Bcl-XL were also downregulated by Sorafenib in primary hepatocytes that lacked caspase-3 activation. Second, previous studies suggested that spontaneous liver apoptosis after genetic inhibition of Mcl-1 and/or Bcl-Xl is most likely caused by latent expression of extrinsic death ligands such as Fas. 23, 24 It has been reported that Sorafenib induces apoptosis via PUMA in a p53-independent manner at least in colon carcinoma cells. 15 In addition, PUMA is downregulated in liver after PH. 25 Our own data showed robust PUMA protein expression in hepatoma cells with or without Sorafenib treatment while PUMA remained at low level in primary hepatocytes in vitro and was even downregulated in liver after PH. It is therefore tempting to speculate that Sorafenib induces hepatoma cell apoptosis in a PUMA-dependent manner, while hepatocytes are protected from Sorafenib-mediated apoptosis if PUMA is downregulated or absent. For our studies on Sorafenib in mice we dissolved the drug in an aqueous solution containing ethanol (8.75%), based on the manufacturer's recommendation and similar to previous animal studies. 6, 26, 27 Unexpectedly, control experiments using the solvent alone already had profound inhibitory effects on cell cycle progression in mice after PH, which have not been addressed before. Since patients receive Sorafenib medication in tablets, these findings do not have an impact for human therapy. However, the strong effect of the ethanol/ chremophor solvent on liver regeneration and potentially also on tumor cell proliferation could require a re-evaluation of some previous data gained in murine models.
Our data on the impact of Sorafenib for liver regeneration in mice expands a recent study by Hora et al. 26 While these authors demonstrated that Sorafenib administration after hepatectomy affected late liver regeneration, our own study was rather focused on early liver regeneration (48 h post PH), liver injury and the underlying signal transduction pathways. We clearly demonstrate that Sorafenib cannot induce caspase-3-mediated apoptosis in liver after PH. However, Sorafenib frequently caused aberrant mitosis reflecting signs of mitotic catastrophe as reviewed recently, which correlated with elevated serum transaminases and thus with increased liver injury. It has been suggested that mitotic catastrophe correlates with incomplete DNA synthesis and premature chromosome condensation that eventually may lead to apoptosis or necrotic-like cell death. 28 Our data from PH experiments revealed that the number of total mitosis events is similar between the Sorafenib-and solvent-treated groups while protein levels of Cyclin B1 (driving mitosis) and Cyclin A2 (driving DNA synthesis) are substantially reduced in the Sorafenib-treated cohort. We therefore conclude that the strong mitogen stimulation after PH (by exocrine mediators such as TNF, EGF, HGF and insulin) in combination with stringent inhibition of downstream Cyclins (E, A and B) may result in faulty DNA replication and irregular mitosis. Future histological analysis of biopsies from patients undergoing Sorafenib therapy would be necessary to evaluate whether our findings are also of clinical relevance.
Taken together, our results highlight the benefit of Sorafenib for specifically eliminating malignant hepatoma cells through apoptosis presumably in a PUMA-dependent manner. However, our study also revealed that Sorafenib may impair liver regeneration by inducing enhanced mitotic failure of healthy hepatocytes and tissue injury, which identifies a yet unknown risk factor.
Materials and Methods
Housing and treatment of mice. All animals were maintained in the animal facility of the University Hospital Aachen in a temperature-controlled room with 12-hour light/dark cycle and free access to food and water. Experimental animal procedures were approved by the authority for environment conservation and consumer protection of the state North Rhine-Westfalia (LANUV, Germany, AZ84-02.04.2011.A365). For the studies, WT mice in a C57BL/6 background were used. PH was performed as described earlier. 29 For any indicated time point and condition, 3-11 mice of male gender at the age of 6-8 weeks were analyzed.
Measurement of aminotransferase activity. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities were measured in serum from mice according to standard methods (UV test at 37 1C) using a Roche Modular preanalytics system (Roche, Grenzach, Germany).
Cell culture procedures. Hepa1-6 hepatoma cells were derived from C57L/J mice 9 and obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany). Primary hepatocytes were isolated from C57BL/6 mice as described recently. 30 All cells were cultured in Dulbecco's Modified Eagle's Medium (PAA, Pasching, Austria) with 10% fetal calf serum at 37 1C in a humidified atmosphere containing 5% CO 2 . For mitogen stimulation, hepatocytes were treated with 10 ng/ml EGF (Sigma-Aldrich, St. Louis, MO, USA) and 0.02 U/ml Insulin (Novo Nordisk, Mainz, Germany).
Application of Sorafenib (Bay 54-9085) in vitro and in vivo. Sorafenib tyoslate was provided by Bayer HealthCare AG Pharmaceuticals (Berlin, Germany). For in vitro studies, Sorafenib was dissolved in DMSO. For in vivo application, Sorafenib was dissolved in an aqueous solution containing 8.75% ethanol and 12.5% Chremophor EL. Sorafenib or solvent were administrated to mice at a dosage of 100 mg/kg by gavage in a total volume of 200 ml.
Quantitative real-time PCR (qPCR). Total RNA from murine hepatoma cells, primary hepatocytes and liver tissues was isolated using the peqGOLD RNAPure Kit (Peqlab, Erlangen, Germany). Reverse transcription was performed using an Omniscript RT Kit (Qiagen, Hilden, Germany). Relative quantitative gene expression was measured via real-time PCR using a 7300 Real Time PCR System with SDS software 1.3.1 (Applied Biosystems, Foster City, CA, USA) and a SYBR Green PCR Kit (Invitrogen, Carlsbad, CA, USA). Target gene expression was normalized by determining GAPDH expression as internal standard and calculated as fold induction in comparison to untreated controls. The primer sequences are given in Supplementary Table 1 .
Liver histology, in situ tissue staining and immunoblot analysis. Standard tissue stainings and immunohistochemistry were performed in the Department of Pathology at the University Hospital Aachen and analyzed by an experienced pathologist (N.G.). For quantitative analysis of Hematoxylin & Eosin (H&E) and chloroacetate esterase (CAE)-stained sections, one high-power field (HPF) was defined as an area of 237 mm 2 at a magnification of Â 200. For the determination of DNA synthesis (S-Phase) in Hepa1-6 cells, primary hepatocytes and the regenerating liver, incorporation of BrdU (Applichem, Cheshire, CT, USA) was analyzed as described recently. 31 In cultured cells, BrdU was added to the cell culture medium at a concentration of 6 mg/ml 2 h before fixation. For the evaluation of cell cycle activity in situ liver cryosections of 5 mm were stained with an anti-Ki-67 antibody. Stained microscopic images were acquired at magnifications of Â 200 with a Zeiss Axio Imager.Z1 microscope, Axiocam MRm and HRc cameras using Axiovision 4.8 software (all from Carl Zeiss, Inc., Oberkochen, Germany). Isolation of whole-cell proteins from cultured cells and liver tissue and subsequent western blot analysis was performed as described previously. 32 Antibodies used for analysis are listed in Supplementary  Table 2 . GAPDH and b-actin were used as loading controls. For the detection of cleaved caspase-3 via immunoblot analysis in whole-cell extracts of isolated primary hepatocytes and livers, murine Hepa1-6 hepatoma cells were treated with 50 mm Sorafenib for 24 h and were used as a positive control (pos.). Immunoblots were visualized by Amersham ECL Prime (GE Healthcare) using the Fuji LAS-4000 Mini, according to the manufacturers' protocol.
Fluorescence-activated cell sorting of Hepa1-6 cells. Cultivated Hepa1-6 cells were harvested with Trypsin (PAN Biotech, Aidenbach, Germany) after 24 h, washed with phosphate-buffered saline and fixated with 4% paraformaldehyde for 15 min. After fixation cells were permeabilized in Nicoletti Buffer (0.1% sodium citrate, 0.1% Triton 100) for 20 min, stained with PI/RNASE staining Buffer (BD Bioscience, Heidelberg, Germany) and analyzed on a FACS Canto II Flowcytometer (BD). Data were analyzed using FlowJo 7.5 Software (Tree Star, Ashland, OR, USA).
Determination of apoptosis. In situ, apoptosis was determined on liver cryosections or on Hepa1-6 cells that adhered to coverslips using an In Situ Cell Death Detection Kit (Roche Diagnostics, Mannheim, Germany) according to manufacturer's instructions. Alternatively, apoptosis was determined by quantification of specific caspase-3 enzyme activity (fluorescence units/mg protein) in protein lysates from cultured cells as described recently. 33 In brief, protein lysates were incubated with the artificial substrate AFC-DEVD (Enzo Life Sciences, Farmingdale, NY, USA) and the caspase-3 mediated release of AFC from DEVD was quantified by UV spectrometry. For determination of cleaved caspase-3 activity in whole-cell extracts of isolated primary hepatocytes and livers, murine Hepa1-6 hepatoma cells were treated with 50 mm Sorafenib for 24 h and were used as a positive control (pos.) Statistical analysis. Data were presented as mean±standard deviation of the mean. Statistical significance was determined by Student's t-test.
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